Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Fair Value

Margin Of Safety %

Put/Call OI Ratio

Float Short​ %​

0.99

EPS 1 Diff

-0.19

EPS Year Diff

-1.76

Ticker: SPRO




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2024-09-06SPRO1.320.000.00426
2024-09-09SPRO1.350.000.00426
2024-09-10SPRO1.360.000.00426
2024-09-11SPRO1.33070.000.00426
2024-09-12SPRO1.330.000.00426
2024-09-13SPRO1.3650.000.00656
2024-09-16SPRO1.370.000.00656
2024-09-17SPRO1.340.000.00916
2024-09-18SPRO1.340.000.00916
2024-09-19SPRO1.350.000.00916
2024-09-20SPRO1.3350.000.00916
2024-09-23SPRO1.3050.000.00916
2024-09-24SPRO1.280.000.00916
2024-09-25SPRO1.280.000.00965
2024-09-26SPRO1.2750.000.00975
2024-09-27SPRO1.30.000.00975
2024-09-30SPRO1.350.000.00976
2024-10-01SPRO1.320.000.00976
2024-10-02SPRO1.30.000.00976
2024-10-03SPRO1.2950.000.00971
2024-10-04SPRO1.280.000.00971
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2024-09-06SPRO1.32-733.3- -1.33
2024-09-09SPRO1.37-733.3- -1.33
2024-09-10SPRO1.35-733.3- -1.33
2024-09-11SPRO1.34-733.3- -1.33
2024-09-12SPRO1.32-733.3- -1.33
2024-09-13SPRO1.37-733.3- -1.33
2024-09-16SPRO1.37-733.3- -1.33
2024-09-17SPRO1.33-733.3- -1.33
2024-09-18SPRO1.34-733.3- -1.33
2024-09-19SPRO1.35-733.3- -1.33
2024-09-20SPRO1.32-733.3- -1.33
2024-09-23SPRO1.30-733.3- -1.33
2024-09-24SPRO1.28-733.3- -1.33
2024-09-25SPRO1.27-733.3- -1.33
2024-09-26SPRO1.28-733.3- -1.33
2024-09-27SPRO1.31-733.3- -1.33
2024-09-30SPRO1.33-733.3- -1.33
2024-10-01SPRO1.34-733.3- -1.33
2024-10-02SPRO1.31-733.3- -1.33
2024-10-03SPRO1.29-733.3- -1.33
2024-10-04SPRO1.30-733.3- -1.33
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2024-09-06SPRO-0.28-5.110.97
2024-09-09SPRO-0.28-5.110.97
2024-09-10SPRO-0.28-5.110.97
2024-09-11SPRO-0.28-5.110.97
2024-09-12SPRO-0.28-5.111.05
2024-09-13SPRO-0.28-5.111.05
2024-09-16SPRO-0.28-5.111.05
2024-09-17SPRO-0.28-5.111.05
2024-09-18SPRO-0.28-5.111.05
2024-09-19SPRO-0.28-5.111.05
2024-09-20SPRO-0.28-5.111.05
2024-09-23SPRO-0.28-5.111.05
2024-09-24SPRO-0.28-5.111.05
2024-09-25SPRO-0.28-5.110.99
2024-09-26SPRO-0.28-5.110.99
2024-09-27SPRO-0.28-5.110.99
2024-09-30SPRO-0.28-5.110.99
2024-10-01SPRO-0.28-5.110.99
2024-10-02SPRO-0.28-5.110.99
2024-10-03SPRO-0.28-5.110.99
2024-10-04SPRO-0.28-5.110.99
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.33

Avg. EPS Est. Current Quarter

-0.5

Avg. EPS Est. Next Quarter

-0.52

Insider Transactions

-0.28

Institutional Transactions

-5.11

Beta

0.62

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

3

Fair Value (Academic)

Quality Score

67

Growth Score

57

Sentiment Score

71

Actual DrawDown %

94.5

Max Drawdown 5-Year %

-96.9

Target Price

7.5

P/E

3.88

Forward P/E

PEG

0.11

P/S

0.67

P/B

0.87

P/Free Cash Flow

EPS

0.34

Average EPS Est. Cur. Y​

-1.33

EPS Next Y. (Est.)

-1.33

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

16.56

Relative Volume

1.54

Return on Equity vs Sector %

0.1

Return on Equity vs Industry %

-21.1

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Spero Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 46
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
stock quote shares SPRO – Spero Therapeutics, Inc. Stock Price stock today
news today SPRO – Spero Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SPRO – Spero Therapeutics, Inc. yahoo finance google finance
stock history SPRO – Spero Therapeutics, Inc. invest stock market
stock prices SPRO premarket after hours
ticker SPRO fair value insiders trading